BioWorld

Aug. 11, 2008

Metabasis Gets $10M Up Front in Roche HepDirect Collaboration

Metabasis Therapeutics Inc. signed a $203 million research collaboration with F. Hoffmann La-Roche Ltd., resulting in some much-needed validation for its HepDirect liver-targeting technology as well as a boost to its stock price and cash balance. (BioWorld Today) Read More

Adipose Stem Cell Firm Cytori Adds $17M for Celution, Trials

Sense-Antisense Pair Feeds Each Other, Amyloid Plaques

New CDC Reports Shed Light on HIV Incidence and Testing

Scientists Create Specific Cell Lines for 10 Diseases

Earnings Roundup

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2026.

ASCO 2026: A revolution in pancreatic cancer

BioWorld

At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

EASL 2026: Emerging liver disease targets to watch

BioWorld

At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...

Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow

ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out

BioWorld

Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...